Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms 177Lu-DansyI-PSMA, 177Lu-LNC1011 |
Target |
Mechanism PSMA modulators(Prostate-specific membrane antigen modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 1 | CN | 05 Apr 2024 | |
Prostatic Cancer | IND Approval | CN | 02 Aug 2024 | |
PSMA-Positive Prostatic Cancer | IND Approval | US | 02 Jul 2024 | |
Solid tumor | Preclinical | - | 25 Mar 2024 |
Not Applicable | - | [177Lu]Lu-LNC1011 1.85 GBq | tjkcorkkhd(oabzueojej) = No life-threatening adverse events were observed during the dosing observation period rqumwoaucz (sstdjtootq ) View more | - | 09 Jun 2024 | ||
[177Lu]Lu-LNC1011 3.7 GBq |